4_NMS Group S.p.A.
|Headquartered in Nerviano, near Milan, Italy, NMS Group S.r.l. (“NMS” or the “Group”) is a group of fully integrated companies owned by Lombardy Region through the Regional Foundation for Biomedical Research (“FRRB”), focused on oncology drug discovery, preclinical research, clinical development and manufacturing.
The Group is powered by its core engine of innovation, as evidenced by its robust portfolio of 1,300+ patents of which 1,000+ are granted.
|On March 28th, 2018 the Shanghai Advanced Research Institute (“SARI”) closed the acquisition of a 90% stake in the Group by way of subscription of a capital increase.
SARI was jointly established by Chinese Academy of Sciences and Shanghai Municipal Government in 2009, and officially launched in 2012, with the purpose to conduct innovative research in a broad range of scientific fields and the aim to foster collaboration between academia and industry. SARI focuses on investment in cutting-edge bio-technology and life-science opportunities, especially targeted cancer therapy.
Following the transaction, FRRB remains as a shareholder of NMS with a stake equal to 10% of issued share capital and SARI holds a stake equal to 90%.
|Leonardo & Co. Role|
|Leonardo & Co., in association with Houlihan Lokey, served as the exclusive financial advisor to NMS, assisting the Group in negotiating the capital increase provided by SARI.
The transaction highlights our ability to channel international funds towards opportunities in niche markets.